gilead pharma hiv hepatitis pricing sovaldi truvada prep lobbying
related: AbbVie Merck Pfizer PhRMA
Who They Are
Gilead Sciences Inc. A biopharmaceutical company ($27 billion revenue, 2024) headquartered in Foster City, California, specializing in antiviral drugs. Gilead’s political significance stems from two products: Sovaldi/Harvoni (hepatitis C cure, $84,000 per course of treatment at launch) and Truvada/Descovy (HIV prevention drug developed with $50+ million in federal research funding, priced at $2,000/month). Gilead PAC contributes $1-2 million per cycle, with $5-8 million in annual lobbying.
What They Want
Patent protection for antiviral portfolio, opposition to drug importation, favorable Medicare Part D negotiation terms, reduced 340B program eligibility (the federal program that requires discounts for safety-net hospitals), and international trade enforcement of intellectual property protections.
What They’ve Gotten
The Sovaldi Pricing Model: Sovaldi’s 2013 launch at $84,000 per 12-week treatment course ($1,000 per pill) became the defining case study of pharmaceutical pricing power. The drug cured hepatitis C — a genuine medical breakthrough — but the price forced state Medicaid programs to ration access, creating waiting lists for a cure. Gilead earned $12.4 billion from Sovaldi in its first year alone. The pricing strategy: charge the maximum that insurance systems will bear, then defend the price through lobbying.
Taxpayer-Funded PrEP: Truvada for PrEP (pre-exposure prophylaxis for HIV prevention) was developed with $50+ million in CDC and NIH research funding. The federal government held a patent on the PrEP application of the drug. Gilead priced Truvada at $2,000/month while the government patent was in effect, generating billions from a publicly funded discovery. The Trump administration sued Gilead over the patent in 2019, but the case was settled without Gilead paying significant damages.
Money
Gilead’s pricing model represents the pharmaceutical industry’s extraction logic at its purest: Sovaldi cures hepatitis C (genuine value), but at $84,000 per treatment course, that cure was rationed by cost — forcing Medicaid programs to create waiting lists for a disease that had a cure. Truvada’s pricing illustrates the socialized-risk-privatized-reward model: $50+ million in federal research funding developed the PrEP application, Gilead priced it at $2,000/month, and the federal government’s patent enforcement was too weak to prevent the extraction. The pattern: public investment creates the knowledge, private companies capture the value, and lobbying prevents price regulation.
Sources
content-readiness:: ready